Skip Navigation

Cardiovascular Research 2003 60(3):460-462; doi:10.1016/j.cardiores.2003.10.007
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zimmermann, W.-H.
Right arrow Articles by Eschenhagen, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zimmermann, W.-H.
Right arrow Articles by Eschenhagen, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Tissue engineering of aortic heart valves

Wolfram-Hubertus Zimmermann* and Thomas Eschenhagen

Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany

*Corresponding author. Tel.: +49-40-42803-3180; fax: +49-40-42803-4876. Email address: w.zimmermann@uke.uni-hamburg.de

Received 1 October 2003; accepted 7 October 2003

The first 10% of the full text of this article appears below.

See article by Schenke-Layland et al. (pages 497–509) in this issue.


   1. Introduction
 
Valve replacement is the most common surgical procedure in patients with advanced valvular heart disease [1]. Extensive experience has been gained with mechanical and decellularized biological valve prostheses since their clinical implementation in 1965 [2]. In the year 2000, 87,000 valve replacement procedures were performed in the US (www.americanheart.org). Despite its indisputable clinical value, currently employed concepts are hampered by thromboembolic complications, infections, limited durability, and lack of growth potential. Tissue engineering approaches hold the promise of generating completely biological, autologous "living" valves with functional features of their native counterparts that may overcome the present limitations [3,4].

Two main . . . [Full Text of this Article]


   2. Decellularization and cell seeding
 

   3. In vitro conditioning and testing
 

   4. Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Circ. Res.Home page
I. Vesely
Heart Valve Tissue Engineering
Circ. Res., October 14, 2005; 97(8): 743 - 755.
[Abstract] [Full Text] [PDF]